@FiercePharma: Two drugmakers hit the Forbes "Fab 50" in Asia: Australia's CSL and India's Sun Pharma. Item | Follow @FiercePharma
> Novartis ($NVS) won FDA approval for a new formulation of its Afinitor cancer treatment, Afinitor Disperz, for children with a rare type of brain tumor. Report
> On the heels of an FDA panel recommendation in the U.S., Abbott Laboratories' ($ABT) Humira nabbed a new use in Europe in patients with moderately active Crohn's disease. Report
> GlaxoSmithKline ($GSK) said it would continue to negotiate with local officials in Montrose, Scotland, after officials rejected its wind-turbine plan designed to power a local plant that's slated for expansion. Report
> Brazil's Hypermarcas is reaping the rewards of a restructuring that refocused its operations on drugs and beauty products. Report
> Quality Packaging Specialists, a New Jersey pharma packaging firm, will move a plant to Pennsylvania and create 283 jobs there over the next three years, officials said. Report
> Switzerland's Siegfried said its active pharmaceuticals ingredient business grew by 2.9% for the first 6 months of 2012, to $185 million, as it prepares to expand operations in China. Report
> China's Fosun Pharma nabbed $47 million in financing from the World Bank's International Finance Corporation, to upgrade manufacturing facilities, including those in less-developed regions. Report
@FierceMedDev: Bacterin International, a maker of bone graft material and antimicrobial coatings, won $25M in financing from OrbiMed. Release | Follow @FierceMedDev
@MarkHFierce: BSX is slashing more jobs and splitting its cardio business in two--undoing changes enacted by the old CEO. More | Follow @MarkHFierce
@DamianFierce: Baxter is recalling four Automix devices over a deadly malfunction risk. The FDA has labeled it a Class I. News | Follow @DamianFierce
> Zynex gets 510(k) for urinary incontinence device. News
> MDxHealth's revenues soar, losses deepen in H1. Item
Biotech News
@FierceBiotech: XBiotech hatches big plans for Austin campus. Item | Follow @FierceBiotech
@JohnCFierce: At long last, Ironwood gets its OK, shifts to commercialization alongside development. News | Follow @JohnCFierce
@RyanMFierce: After reading through this OvaScience S-1, looks like VCs are in fact cashing out, some want to unload most of their shares. | Follow @RyanMFierce
> Cincy biotech spinoff snags $27M A round for vascular drug work. Story
> Novartis ready to present blockbuster COPD hopeful QVA149 to regulators. Article
> Teva's Neupogen-knockoff approval highlights slow progress of biosims. More
> J&J grabs Genmab's promising leukemia antibody in $1.1B deal. News
Pharma Manufacturing News
@EricPFierce: Hospira goes back to Orchid, picks up API plant, R&D center for $200 million. Good news tainted a bit by FDA warning. Story | Follow @EricPFierce
> Closed plants lead Novartis to plead for vet loyalty. Story
> Claris squares off against former partners in U.S. injectables market. Article
> Scots reject GSK wind turbines; tidal turbines up next. Story
Vaccines News
@AlisonBFierce: What does AstraZeneca's new CEO mean to vaccinemaker MedImmune? More | Follow @AlisonBFierce
> S. Korea, Sweden partner up to find Alzheimer's vaccine. Item
> West Nile virus breaks out in the South. News
> CSL nets closeout letter after FDA violations. More
> Flu adjuvant adds promise to vaccine. Report
And Finally ... Tuberculosis cases around the world are growing increasingly resistant to virtually all treatments, a study found. Report